Publication

Article

Oncology Treatment Pathways®
November 2022

Novel Targeted Immunotherapies in Multiple Myeloma, With a Focus on Bispecific Antibodies

Download Issue PDF
Articles in this issue
Novel Targeted Immunotherapies in Multiple Myeloma, With a Focus on Bispecific Antibodies
Novel Targeted Immunotherapies in Multiple Myeloma, With a Focus on Bispecific Antibodies
Related Videos
Marc Machaalani, MD
Marco Davila, MD, PhD
Danielle E. Hammond, MD, FRCP(C)
Salman R. Punekar, MD
Thomas Marron, MD, PhD
D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD
Manmeet Singh Ahluwalia, MD
D. Ross Camidge, MD, PhD
Related Content
FDA recap thumb
October 4th 2024

OncLive’s September Roundup of Key FDA Approvals in Oncology

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC
November 18th 2021

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

The FDA’s ODAC votes against the risk:benefit profile of frontline PD-1 inhibitors in select tumor types, osimertinib gains approval for select NSCLC, and more this week from OncLive.
September 28th 2024

The OncFive: Top Oncology Articles for the Week 9/22

Gordan on Growing the Infrastructure for In-House Genomic Testing
October 14th 2021

Gordan on Growing the Infrastructure for In-House Genomic Testing

FDA
September 25th 2024

FDA Approves Osimertinib for Locally Advanced, Unresectable EGFR+ NSCLC After Chemoradiation

The FDA has granted fast track designation to EO-3021 for use in select patients with claudin 18.2–expressing gastric or GEJ cancer.
September 24th 2024

FDA Grants Fast Track Status to EO-3021 for CLDN18.2-Expressing Gastric or GEJ Cancer